Onxeo SA Valuation
| C4X Stock | EUR 0.07 0.0001 0.14% |
Onxeo SA seems to be overvalued based on Macroaxis valuation methodology. Our model determines the value of Onxeo SA from analyzing the company fundamentals such as Current Valuation of 5.34 M, return on equity of -0.4, and Shares Owned By Insiders of 13.25 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Onxeo SA's price fluctuation is out of control at this time. Calculation of the real value of Onxeo SA is based on 3 months time horizon. Increasing Onxeo SA's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Onxeo stock is determined by what a typical buyer is willing to pay for full or partial control of Onxeo SA. Since Onxeo SA is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Onxeo Stock. However, Onxeo SA's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0706 | Real 0.0663 | Hype 0.07 | Naive 0.0704 |
The real value of Onxeo Stock, also known as its intrinsic value, is the underlying worth of Onxeo SA Company, which is reflected in its stock price. It is based on Onxeo SA's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Onxeo SA's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Onxeo SA helps investors to forecast how Onxeo stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Onxeo SA more accurately as focusing exclusively on Onxeo SA's fundamentals will not take into account other important factors: Onxeo SA Total Value Analysis
Onxeo SA is currently estimated to have takeover price of 5.34 M with market capitalization of 37.98 M, debt of 9.91 M, and cash on hands of 24.46 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Onxeo SA fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.34 M | 37.98 M | 9.91 M | 24.46 M |
Onxeo SA Investor Information
About 13.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.48. Some equities with similar Price to Book (P/B) outperform the market in the long run. Onxeo SA recorded a loss per share of 0.11. The entity had not issued any dividends in recent years. Based on the key measurements obtained from Onxeo SA's financial statements, Onxeo SA is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Onxeo SA Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Onxeo SA has an asset utilization ratio of 7.66 percent. This implies that the Company is making €0.0766 for each dollar of assets. An increasing asset utilization means that Onxeo SA is more efficient with each dollar of assets it utilizes for everyday operations.Onxeo SA Ownership Allocation
Onxeo SA owns a total of 111.06 Million outstanding shares. Onxeo SA holds 13.25 pct. of its outstanding shares held by insiders and 12.72 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Onxeo SA Profitability Analysis
The company reported the revenue of 4.06 M. Net Loss for the year was (5.94 M) with profit before overhead, payroll, taxes, and interest of 3.69 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Onxeo SA's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Onxeo SA and how it compares across the competition.
About Onxeo SA Valuation
The stock valuation mechanism determines Onxeo SA's current worth on a weekly basis. Our valuation model uses a comparative analysis of Onxeo SA. We calculate exposure to Onxeo SA's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Onxeo SA's related companies.Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. Onxeo SA was incorporated in 1997 and is headquartered in Paris, France. ONXEO S operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 29 people.
8 Steps to conduct Onxeo SA's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Onxeo SA's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Onxeo SA's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Onxeo SA's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Onxeo SA's revenue streams: Identify Onxeo SA's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Onxeo SA's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Onxeo SA's growth potential: Evaluate Onxeo SA's management, business model, and growth potential.
- Determine Onxeo SA's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Onxeo SA's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Onxeo Stock analysis
When running Onxeo SA's price analysis, check to measure Onxeo SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Onxeo SA is operating at the current time. Most of Onxeo SA's value examination focuses on studying past and present price action to predict the probability of Onxeo SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Onxeo SA's price. Additionally, you may evaluate how the addition of Onxeo SA to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Commodity Directory Find actively traded commodities issued by global exchanges |